Search

Semi-synthetic cannabinoids (SSCs) are becoming more popular as legal replacement of tetrahydrocannabinol (THC). Products containing hexahydrocannabinol (HHC), hexahydrocannabiphorol (HHC-P), tetrahydrocannabiphorol (THC-P) and tetrahydrocannabidiol (H4-CBD) are readily available in e.g. kiosks or online shops. As soon as a compound becomes illegal, both as narcotics and regarding driving under the influence of drugs (DUID), the next analogue takes over the market. Therefore, it is difficult to predict what should be detectable in DUID cases. In Copenhagen, both analysis of seized drugs and biological samples are being performed at the Section of Forensic Chemistry. The information regarding which compounds are found in seized materials can be valuable for the toxicological investigations of forensic cases. At our section, HHC was first observed in seized materials in 2022. It was present in 135 seized materials received from police and customs in Eastern Denmark in 2022–2023. In the same period, HHC-P, THC-P and H4-CBD were detected in 20, 9 and 53 seized materials, respectively. With this information in mind, we developed an analytical strategy for including SSCs in our LC-MS/MS analysis of biological samples, including those from DUID cases. HHC was scheduled as a narcotic substance in Denmark in May 2023 followed by HHC-P, THC-P and H4-CBD in January 2024. Of the earlier mentioned seized materials containing HHC, 33% of these were collected after it was declared illegal. HHC-P, THC-P and H4-CBD only became prominent after illegalization of HHC, where 94% of the mentioned cases were confiscated after HHC was prohibited. Targeted screening of the new SSCs were included in our routine LC-MS/MS analysis for quantification of THC in blood from DUID cases. Purchased reference material of the compounds were used to prepare a spiked cut-off QC in blood. Positive findings of HHC, HHC P, THC-P and H4-CBD above the cut-off were rare in blood sam

Drug concentrations in peripheral blood are often used to evaluate whether death was caused by drug intoxication. In some cases, peripheral blood is not available, and analytical results of alternative matrices should instead be used in the toxicological evaluation. However, reference concentrations of alternative matrices are few, which makes interpretation of results a challenge. In this study, concentrations of selected benzodiazepines, opioids, illicit drugs, and other commonly used drugs in postmortem femoral blood, cardiac blood, brain tissue, and muscle tissue are presented. Alternative matrix-to-femoral blood drug concentration ratios and correlations of blood and alternative matrix drug concentrations were calculated to examine which of the investigated alternative matrices were most suited to use for toxicological evaluation in cases where peripheral blood is not available. The results showed that concentrations in cardiac blood, brain tissue, and muscle tissue could be useful in the postmortem evaluation of most of the 19 selected analytes. In most cases, analytes were detected in all the alternative matrices. The median concentration ratios for the selected analytes in brain tissue, cardiac blood, and muscle tissue relative to femoral blood ranged from 0.57 to 3.42, 0.59 to 1.87, and 0.67 to 7.04, respectively. Overall, cardiac blood provided the concentrations most comparable with femoral blood concentrations, indicating that cardiac blood can be useful in cases where femoral blood is not available. However, the measured concentrations should be interpreted with caution., Drug concentrations in peripheral blood are often used to evaluate whether death was caused by drug intoxication. In some cases, peripheral blood is not available, and analytical results of alternative matrices should instead be used in the toxicological evaluation. However, reference concentrations of alternative matrices are few, which makes interpretation of results a challenge. In this study, concentrations of selected benzodiazepines, opioids, illicit drugs, and other commonly used drugs in postmortem femoral blood, cardiac blood, brain tissue, and muscle tissue are presented. Alterna- tive matrix-to-femoral blood drug concentration ratios and correlations of blood and alternative matrix drug concentrations were calculated to examine which of the investigated alternative matrices were most suited to use for toxicological evaluation in cases where peripheral blood is not available. The results showed that concentra- tions in cardiac blood, brain tissue, and muscle tissue could be useful in the postmor- tem evaluation of most of the 19 selected analytes. In most cases, analytes were detected in all the alternative matrices. The median concentration ratios for the selected analytes in brain tissue, cardiac blood, and muscle tissue relative to femoral blood ranged from 0.57 to 3.42, 0.59 to 1.87, and 0.67 to 7.04, respectively. Overall, cardiac blood provided the concentrations most comparable with femoral blood con- centrations, indicating that cardiac blood can be useful in cases where femoral blood is not available. However, the measured concentrations should be interpreted with caution. KEYWORDS

Alternative specimens collected during autopsies can be valuable in postmortem toxicology in cases where peripheral blood is not available. The applicability of brain tissue as an alternative matrix for drug screening by ultra-high-performance liquid chromatography–quadrupole time-of-flight mass spectrometry was investigated in this study. Results of the 50 most frequently detected drugs and metabolites of toxicological interest in blood and brain tissue samples from 1,719 autopsy cases were compared. Examination of the results in paired blood and brain tissue samples revealed that the two matrices were in general comparable, as the majority of the 50 analytes were observed in a high number of the examined cases in both blood and brain tissue. This demonstrates the potential of brain tissue as an alternative matrix for drug screening in postmortem toxicology or as a secondary matrix for confirmation.

Aim Drug concentrations in peripheral blood are most often used in interpretation of toxicological results in postmortem cases. However, peripheral blood is not always available or suitable for analysis, especially in advanced stages of decomposition. Therefore, other matrices than peripheral blood need to be investigated in order to reveal the cause of death. However, there is no obvious second choice. In this study, we analyzed postmortem femoral blood, cardiac blood, brain tissue and muscle tissue in order to investigate if drug concentrations in these alternative matrices were comparable to femoral blood and thereby useful for toxicological interpretation. Method A total of 104 consecutive autopsies where toxicological investigation was included were performed in a four-month period. Femoral blood (n = 89), cardiac blood (n = 85), brain tissue (n = 91) and muscle tissue (n = 104) were analyzed in all cases when available. Quantification of 69 common drugs and metabolites of toxicological interest was performed with four different multi-analyte methods all employing automated sample preparation and UHPLC MS/MS in MRM mode. Results In 104 autopsy cases, we were able to detect a total of 53 drugs and metabolites. Alternative matrix to femoral blood concentration ratios were calculated for 47 analytes for cardiac blood, 49 analytes for brain tissue and 50 analytes for muscle tissue, respectively. However, about half of the analytes were only detected in < 5 cases. Median ratios of analytes detected in ≥ 5 cases were determined to 0.59–1.9 (median = 1.1) for cardiac blood to femoral blood, 0.57–2.5 (median = 1.5) for brain tissue to femoral blood and 0.67–7.0 (median = 1.4) for muscle tissue to femoral blood. The largest deviation in ratios was observed for THC in muscle tissue. Here muscle tissue to femoral blood ratios varied from 2.3 to 20 with a median of 7.0 (n = 10). It is, however, a well-known fact that quantitative analysis o

Precision (or imprecision) is one of the central performance parameters of all analytical methods. It is often evaluated during method validation in spiked samples, with a relatively low number of measurements typically during a short period. Validation results are well documented in the literature; however, evaluation of imprecision in authentic cases compared with long-term imprecision from quality control samples has not often been reported on. The aim of this study was to investigate imprecision estimated from duplicate measurements of ante- and postmortem blood samples and long-term imprecision estimates from quality control samples and to compare variations between them. Data were analyzed by using robust statistics, where results for the 29 analytes most frequently quantified by liquid chromatography–tandem mass spectrometry in ante- and postmortem blood samples were included. A total of 41,460 positive findings in authentic whole blood and 51,522 measurements from quality controls were investigated. Analysis was performed in duplicate on independent batches on two separate days. Overall, the imprecision estimated in quality control and the authentic samples were akin for most analytes. Ante- and postmortem blood samples showed similar imprecision for the majority of the analytes and were approximately the same level as long-term imprecision estimated from the quality control samples at low level, whereas relative imprecision of the quality control samples at high level were slightly lower than ante- and postmortem blood samples. The methods we evaluated showed satisfactory reproducibility and robustness for the investigated analytes., Precision (or imprecision) is one of the central performance parameters of all analytical methods. It is often evaluated during method validation in spiked samples, with a relatively low number of measurements typically during a short period. Validation results are well documented in the literature; however, eva- luation of imprecision in authentic cases compared with long-term imprecision from quality control samples has not often been reported on. The aim of this study was to investigate imprecision estimated from duplicate measurements of ante- and postmortem blood samples and long-term imprecision esti- mates from quality control samples and to compare variations between them. Data were analyzed by using robust statistics, where results for the 29 analytes most frequently quantified by liquid chromato- graphy–tandem mass spectrometry in ante- and postmortem blood samples were included. A total of 41,460 positive findings in authentic whole blood and 51,522 measurements from quality controls were investigated. Analysis was performed in duplicate on independent batches on two separate days. Overall, the imprecision estimated in quality control and the authentic samples were akin for most analytes. Ante- and postmortem blood samples showed similar imprecision for the majority of the analytes and were approximately the same level as long-term imprecision estimated from the quality control samples at low level, whereas relative imprecision of the quality control samples at high level were slightly lower than ante- and postmortem blood samples. The methods we evaluated showed satisfactory reproducibility and robustness for the investigated analytes.

Whole blood is most often the matrix of choice for postmortem analysis but it is not always available. In these cases, muscle tissue can be used as an alternative matrix. Therefore, an ultra-high-performance liquid chromatography-tandem mass spectrometry method for the quantification of 29 drugs and metabolites of toxicological interest in postmortem muscle tissue was developed and validated. Additionally, a validation of whole blood was carried out to compare the results from the two matrices. Solid-phase extraction was performed by an automated robotic system to minimize manual labour and risk of human errors, and increase robustness, sample throughput and sample traceability. The method was validated in terms of selectivity, matrix effect, extraction recovery, process efficiency, measuring range, lower limit of quantification, carry-over, stability, precision and accuracy. To correct for any inter-individual variability in matrix effects on analyte accuracy and precision, deuterated analogues of each analyte were used as internal standards. The lower limit of quantification in both blood and muscle homogenate ranged between 0.002 and 0.005 mg/kg, while the upper limit of quantification spanned from 0.20 to 1.0 mg/kg. Corrected with the 4-fold dilution factor, the corresponding concentrations in muscle tissue were 0.008-0.02 mg/kg at the lower limit of quantification and 0.80-4.0 mg/kg at the upper limit of quantification. The method showed acceptable precision and accuracy, with precision below 12% and accuracies ranging from 87% to 115% at up to 6 levels for all analytes in both matrices. In addition, comparison between calibration standards in spiked muscle homogenate and spiked blood showed that analyte concentrations in muscle samples could be quantified by using spiked blood samples as calibration standards with acceptable precision and accuracy when using deuterated analogues as internal standards. The investigation of matrix effects showed no great diff

In forensic investigations, such as drug-facilitated crimes, reference values are useful for interpretation of hair results. The aim of this study was to establish levels of zopiclone and two main metabolites, N-desmethylzopiclone and zopiclone N-oxide, in hair after the administration of a single dose of zopiclone, as very limited data are published. A controlled study was performed, where 16 volunteers consumed either 5 or 10mg zopiclone. Hair was sampled prior to consumption and 14, 30, 60, and 120 days after intake. The deposition of drug in hair segments of all sampling time points was followed in small hair segments of 5-mm, using a validated ultra-high performance liquid chromatography-tandem mass spectrometry method. In all participants, hair segments corresponding to the time of intake were positive for zopiclone, but also with lower concentrations in the neighbouring segments. The highest zopiclone concentrations were detected in samples collected 30 or 60 days after intake. For all sampling time points maximum values for the 5-mg dose ranged from 5.0-370pg/mg for zopiclone and 5.4 to 300pg/mg for N-desmethylzopiclone, where the maximum values for the 10-mg dose ranged from 17 to 590pg/mg for zopiclone and 25-410pg/mg for N-desmethylzopiclone for all sampling time points. No significant difference in concentrations was found between the two dosing groups for either zopiclone or N-desmethylzopiclone. Almost half of the participants showed lower levels 14 days after intake than in the later sampling time points. The metabolite to parent drug ratio of N-desmethylzopiclone to zopiclone varied from 0.6 to 3.4 (median=1.2) for the maximum levels of all sampling time points. N-desmethylzopiclone are suggested to serve as an additional marker to confirm the intake of zopiclone. Traces of zopiclone N-oxide were detected in hair from only eight participants. This study showed, that it was possible to follow zopiclone and N-desmethylzopiclone in hair for 4 months